A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

ABSTRACT: Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MR...

Descripción completa

Detalles Bibliográficos
Autores principales: Campisi, Giuseppina, Mauceri, Rodolfo, Bertoldo, Francesco, Fusco, Vittorio, Bedogni, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268308/
https://www.ncbi.nlm.nih.gov/pubmed/34243807
http://dx.doi.org/10.1186/s13005-021-00280-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268308/
https://www.ncbi.nlm.nih.gov/pubmed/34243807
http://dx.doi.org/10.1186/s13005-021-00280-4

Ejemplares similares